Menno Hoekstra1, Mary Sorci-Thomas. 1. aDivision of Biopharmaceutics, Cluster BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden, The Netherlands bDivision of Endocrinology, Department of Pharmacology and Toxicology, Medical College of Wisconsin cBlood Research Institute, Blood Center of Wisconsin, Milwaukee, Wisconsin, USA.
Abstract
PURPOSE OF REVIEW: Scavenger receptor BI (SR-BI) is classically known for its role in antiatherogenic reverse cholesterol transport as it selectively takes up cholesterol esters from HDL. Here, we have highlighted recent literature that describes novel functions for SR-BI in physiology and disease. RECENT FINDINGS: A large population-based study has revealed that patients heterozygous for the P376L mutant form of SR-BI showed significantly increased levels of plasma HDL-cholesterol and had increased risk of cardiovascular disease, demonstrating that SR-BI in humans is a significant determinant of cardiovascular disease. Furthermore, SR-BI has been shown to modulate the susceptibility to LPS-induced tissue injury and the ability of sphingosine 1 phosphate to interact with its receptor, linking SR-BI to the regulation of inflammation. In addition, important domains within the molecule (Trp-415) as well as novel regulators (procollagen C-endopeptidase enhancer protein 2) of SR-BI's selective uptake function have recently been identified. Moreover, relatively high expression levels of the SR-BI protein have been observed in a variety of cancer tissues, which is associated with a reduced overall survival rate. SUMMARY: The HDL receptor SR-BI is a potential therapeutic target not only in the cardiovascular disease setting, but also in inflammatory conditions as well as in cancer.
PURPOSE OF REVIEW: Scavenger receptor BI (SR-BI) is classically known for its role in antiatherogenic reverse cholesterol transport as it selectively takes up cholesterol esters from HDL. Here, we have highlighted recent literature that describes novel functions for SR-BI in physiology and disease. RECENT FINDINGS: A large population-based study has revealed that patients heterozygous for the P376L mutant form of SR-BI showed significantly increased levels of plasma HDL-cholesterol and had increased risk of cardiovascular disease, demonstrating that SR-BI in humans is a significant determinant of cardiovascular disease. Furthermore, SR-BI has been shown to modulate the susceptibility to LPS-induced tissue injury and the ability of sphingosine 1 phosphate to interact with its receptor, linking SR-BI to the regulation of inflammation. In addition, important domains within the molecule (Trp-415) as well as novel regulators (procollagen C-endopeptidase enhancer protein 2) of SR-BI's selective uptake function have recently been identified. Moreover, relatively high expression levels of the SR-BI protein have been observed in a variety of cancer tissues, which is associated with a reduced overall survival rate. SUMMARY: The HDL receptor SR-BI is a potential therapeutic target not only in the cardiovascular disease setting, but also in inflammatory conditions as well as in cancer.
Authors: Ricquita D Pollard; Christopher N Blesso; Manal Zabalawi; Brian Fulp; Mark Gerelus; Xuewei Zhu; Erica W Lyons; Nebil Nuradin; Omar L Francone; Xiang-An Li; Daisy Sahoo; Michael J Thomas; Mary G Sorci-Thomas Journal: J Biol Chem Date: 2015-05-06 Impact factor: 5.157
Authors: Paolo Zanoni; Sumeet A Khetarpal; Daniel B Larach; William F Hancock-Cerutti; John S Millar; Marina Cuchel; Stephanie DerOhannessian; Anatol Kontush; Praveen Surendran; Danish Saleheen; Stella Trompet; J Wouter Jukema; Anton De Craen; Panos Deloukas; Naveed Sattar; Ian Ford; Chris Packard; Abdullah al Shafi Majumder; Dewan S Alam; Emanuele Di Angelantonio; Goncalo Abecasis; Rajiv Chowdhury; Jeanette Erdmann; Børge G Nordestgaard; Sune F Nielsen; Anne Tybjærg-Hansen; Ruth Frikke Schmidt; Kari Kuulasmaa; Dajiang J Liu; Markus Perola; Stefan Blankenberg; Veikko Salomaa; Satu Männistö; Philippe Amouyel; Dominique Arveiler; Jean Ferrieres; Martina Müller-Nurasyid; Marco Ferrario; Frank Kee; Cristen J Willer; Nilesh Samani; Heribert Schunkert; Adam S Butterworth; Joanna M M Howson; Gina M Peloso; Nathan O Stitziel; John Danesh; Sekar Kathiresan; Daniel J Rader Journal: Science Date: 2016-03-11 Impact factor: 47.728
Authors: Erik R Nelson; Suzanne E Wardell; Jeff S Jasper; Sunghee Park; Sunil Suchindran; Matthew K Howe; Nicole J Carver; Ruchita V Pillai; Patrick M Sullivan; Varun Sondhi; Michihisa Umetani; Joseph Geradts; Donald P McDonnell Journal: Science Date: 2013-11-29 Impact factor: 47.728
Authors: Marcus Dorner; Joshua A Horwitz; Justin B Robbins; Walter T Barry; Qian Feng; Kathy Mu; Christopher T Jones; John W Schoggins; Maria Teresa Catanese; Dennis R Burton; Mansun Law; Charles M Rice; Alexander Ploss Journal: Nature Date: 2011-06-08 Impact factor: 49.962
Authors: Srividya Velagapudi; Peter Schraml; Mustafa Yalcinkaya; Hella A Bolck; Lucia Rohrer; Holger Moch; Arnold von Eckardstein Journal: J Lipid Res Date: 2018-09-01 Impact factor: 5.922
Authors: Michela Palmieri; Teenamol E Joseph; Charles A O'Brien; Horacio Gomez-Acevedo; Stavros C Manolagas; Elena Ambrogini Journal: PLoS One Date: 2022-03-29 Impact factor: 3.240
Authors: Katharina Kinslechner; David Schörghofer; Birgit Schütz; Maria Vallianou; Bettina Wingelhofer; Wolfgang Mikulits; Clemens Röhrl; Markus Hengstschläger; Richard Moriggl; Herbert Stangl; Mario Mikula Journal: Mol Cancer Res Date: 2017-10-03 Impact factor: 5.852